Azitra, Inc. (AZTR)

Market Cap	4.55M
Revenue (ttm)	7,500
Net Income (ttm)	-9.10M
Shares Out	17.23M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	542,237
Open	0.2767
Previous Close	0.2855
Day's Range	0.2603 - 0.2797
52-Week Range	0.2325 - 12.0000
Beta	-1.78
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2025

About AZTR

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epider...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2023
• Employees: 12
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: AZTR
• Website: https://azitrainc.com

Financial Performance

In 2024, Azitra's revenue was $7,500, a decrease of -98.91% compared to the previous year's $686,000. Losses were -$8.97 million, -29.05% less than in 2023.